ABIONYX Pharma Releases Shareholder Information: Total Voting Rights and Share Capital Update
Paris, France – July 4, 2025 – ABIONYX Pharma, a biopharmaceutical company dedicated to the development of innovative therapies, today announced important information regarding its share capital and total voting rights. This update, released via Business Wire French Language News, provides shareholders and the market with key figures pertaining to the company’s ownership structure.
The disclosure confirms the total number of shares that comprise ABIONYX Pharma’s share capital, alongside the total number of voting rights attached to these shares. Such transparency is crucial for maintaining a well-informed shareholder base and ensuring compliance with regulatory requirements.
While the specific figures are detailed in the official Business Wire announcement, the release of this information is a routine and essential step for publicly traded companies. It allows investors to accurately assess their stake in the company and to exercise their voting rights effectively during shareholder meetings.
ABIONYX Pharma remains committed to open communication with its stakeholders. This regular provision of information underscores the company’s dedication to good corporate governance and its proactive approach to keeping the market abreast of its operational and financial developments. Investors are encouraged to refer to the official Business Wire announcement for the precise details of the share capital and voting rights.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
Business Wire French Language News published ‘ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social’ at 2025-07-04 16:42. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.